3 min read
A Q&A with Harshvardhan Gummadi, Subject Matter Expert – Regulatory Labeling, Freyr Solutions
Global product approvals are becoming more complex by the year. Health authorities are tightening safety-update timelines, markets are demanding faster simultaneous submissions, and lifecycle management has grown far beyond a one-time approval event. In this environment, Regulatory labeling has quietly evolved from a submission requirement into a strategic function that shapes Regulatory success, market access, and long-term compliance.
To unpack what this shift means for pharmaceutical companies, we sat down with Harshvardhan Gummadi, Subject Matter Expert – Regulatory Labeling at Freyr Solutions, who shares practical insights on building an effective global labeling strategy — from early planning to digital transformation.
The Changing Role of Labeling
Q1. Many organizations still view labeling as a Regulatory deliverable. Why should they think differently?
Labeling is often treated as a document that gets finalized once approval is close. But it influences product development decisions, Regulatory strategy, commercialization timelines, and lifecycle compliance, both before and after approval. A Target Product Profile or Investigator Brochure shapes clinical messaging, informs risk communication, and sets the foundation for every regional label. Treating labeling as a business-critical function — not a documentation exercise — is what separates organizations with smooth global rollouts from those constantly firefighting label discrepancies. Partnering with experienced Regulatory labeling services providers early can help organizations reframe labeling as a strategic driver rather than a compliance checkbox.
Planning Early for Long-Term Success
Q2. When should pharmaceutical companies begin developing their global labeling strategy?
Ideally, well before marketing authorization — during clinical development. Many organizations wait until late-stage submission planning, which forces reactive decisions. Integrating labeling considerations during clinical development allows the Target Product Profile and developmental CCDS to evolve in parallel with clinical data. This early alignment reduces rework, avoids last-minute safety language conflicts, and results in smoother, faster submissions across markets.
Building the Right Foundation
Q3. What are the essential building blocks of a successful global labeling strategy?
Three elements form the core:
- Target Product Profile (TPP): Defines the intended clinical and commercial positioning of the product.
- Target Label Profile (TLP): Translates the TPP into anticipated label content and claims.
- Developmental CCDS: Serves as the evolving reference document that captures key safety and efficacy data as it matures.
Layered across all three are labeling governance, cross-functional collaboration, and structured content management. These aren't separate steps — they run through every stage of label development, ensuring consistency, traceability, and audit-readiness as the product moves toward global authorization.
Managing Global Complexity
Q4. What makes global labeling significantly more challenging than regional labeling?
Regulatory framework differs from country to country and so the labeling requirements. The global label should drive the company position for the product, while satisfying the regional/country labeling requirements. Organizations must maintain global harmonization while still accommodating local Regulatory nuances, template differences, linguistic differences — all while managing simultaneous submission timelines that leave little room for error.
Turning Challenges into Opportunities
Q5. How can organizations balance global consistency with local Regulatory requirements?
The answer lies in a structured framework: a strong global core label, controlled regional adaptation, and clear governance models that define who owns what. Standardized review processes and continuous Regulatory intelligence monitoring help teams anticipate changes rather than react to them. This balance — global consistency with local flexibility — enables companies to scale labeling operations without compromising compliance.
Preparing for Commercialization
Q6. How does a strong labeling strategy accelerate global market authorization?
Rather than accelerating approvals directly, good labeling strengthens everything around them. It improves submission quality, reduces review cycles, and minimizes health authority queries. It also supports launch planning by ensuring commercial and medical teams have accurate, finalized content ready ahead of time, and it simplifies lifecycle management once the product is on the market.
Future-Proofing Labeling Operations
Q7. How is digital transformation reshaping global labeling strategies?
Digital transformation is redefining how labeling teams work. Electronic Product Information (ePI), structured content management, labeling automation, and AI-assisted content generation are moving from pilot projects to operational necessities. Health authorities worldwide are increasingly moving toward digital-first labeling formats, and organizations that build digital labeling readiness now will be far better positioned than those scrambling to catch up later.
Advice for Regulatory Leaders
Q8. If you could recommend one strategic change for pharmaceutical companies today, what would it be?
Start early and build with structure. Early planning, structured governance, lifecycle thinking, cross-functional collaboration, and a culture of continuous improvement are what make global labeling strategies sustainable. Labeling isn't a one-time deliverable — it's an evolving asset that supports the product for its entire commercial life. Organizations that invest in this mindset early will find global growth far less turbulent.
Conclusion
Building a scalable global labeling strategy starts with the right expertise. Freyr Solutions partners with pharmaceutical companies to develop global labeling strategies, establish CCDS governance, manage lifecycle labeling, and support successful market authorizations across worldwide markets. Connect with our experts to streamline your global labeling journey.
About the Expert
Harshvardhan Gummadi is a Subject Matter Expert – Regulatory Labeling at Freyr Solutions, with broad experience across global labeling strategy and regional/country-specific labeling, including developmental and established product CCDS, EU SmPC/PIL, USPI, Japanese Package Insert, and global label creation and maintenance.
